# Core F: Biomarker Core

> **NIH NIH P30** · UNIVERSITY OF KANSAS MEDICAL CENTER · 2021 · $570,988

## Abstract

ABSTRACT: BIOMARKER CORE
 The Biomarker Core performs fluid biomarker assessments for the University of Kansas Alzheimer's
Disease Research Center (KU ADRC). For Cohort participants we determine amyloid-tau-neurodegeneration
(ATN) levels in cerebrospinal fluid (CSF) and plasma; measure plasma inflammation, neurotrophin, and
metabolism-relevant endpoints; and obtain blood and brain mitochondrial DNA (mtDNA) sequences.
 In addition to meeting the Center's need for standard ATN biomarker assessments, the Biomarker Core
maintains the innovation and unique resources of our foundational Mitochondrial Genomics and Metabolism
(MGM) Core. The MGM Core developed novel mitochondrial and metabolism biomarkers and used those
biomarkers as clinical trial target engagement endpoints. It also identified mitochondria and metabolism-
associated diagnostic and prognostic biomarkers. The original MGM Core also offered state-of-the-art
consultation and technical support to investigators and here the Biomarker Core delivers these services. Cell
models available through the MGM Core including cytoplasmic hybrid (cybrid) cell lines, induced pluripotent
stem cell (iPSC) lines, neurons and glia differentiated from iPSCs, and lymphoblast cell lines remain available
through the Biomarker Core.
 Adding ATN assessments enriches our Clinical Cohort dataset and nurtures an emerging ADRD field-wide
interest in correlating ATN biomarkers with mtDNA signatures, mitochondrial function, and energy metabolism.
Extending these services to investigators benefits their research projects and programs. It provides our local,
national, and international users the much-valued metabolism-oriented service, expertise and reagents we
provided during our previous two cycles. It maintains our preeminence in understanding the causes of AD
mitochondrial and energy metabolism dysfunction, the consequences of that dysfunction, and how to
manipulate mitochondria and energy metabolism with therapeutic or prevention intent. During this cycle the
Biomarker Core will accomplish its goals by focusing on the following Specific Aims: (1) Perform fluid and
tissue biomarker assessments; (2) Pursue mitochondrial and metabolism biomarker development; and (3)
Provide cell models, technical services, and novel biomarkers.

## Key facts

- **NIH application ID:** 10264628
- **Project number:** 1P30AG072973-01
- **Recipient organization:** UNIVERSITY OF KANSAS MEDICAL CENTER
- **Principal Investigator:** RUSSELL H. SWERDLOW
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $570,988
- **Award type:** 1
- **Project period:** 2021-08-15 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10264628

## Citation

> US National Institutes of Health, RePORTER application 10264628, Core F: Biomarker Core (1P30AG072973-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10264628. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*